Latest news
FDA approves first-in-class drug to treat narcolepsy - Drug Discovery NewsDrug Discovery News · Fri, 07 Aug 2026 19:48:16 GMTFDA approves Takeda’s first-in-class narcolepsy drug - EMJEMJ · Fri, 07 Aug 2026 15:12:52 GMTFierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 12:35:10 GMTTakeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead - Pharmaceutical TechnologyPharmaceutical Technology · Fri, 07 Aug 2026 09:53:37 GMTTakeda (TAK) Wins FDA Approval For First-In-Class Narcolepsy Drug Orzeyful With $2–3 Billion Peak Sales Target - londoninsider.co.uklondoninsider.co.uk · Fri, 07 Aug 2026 05:51:01 GMTFDA Approves First-in-Class Narcolepsy Drug - MedPage TodayMedPage Today · Thu, 06 Aug 2026 20:46:04 GMTTakeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful - Fierce PharmaFierce Pharma · Thu, 06 Aug 2026 15:10:41 GMTFDA Okays First-in-Class Narcolepsy Drug Oveporexton - MedscapeMedscape · Thu, 06 Aug 2026 13:43:23 GMT